WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2024)
Top diagnostic & research stocks in 2024 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research
OverviewZen ScorePriceValuationFinancialsForecastEarnings & RevenueDividends
OwnershipTechnicals
Ticker
Company
Dividends Score
Market Cap
Dividend Yield
Payout Ratio
Last Dividend
Annual Dividend
Dividend Percentile
Dividend Dropped Count (L10Y)
Ex-dividend Date
Div. Payment Date
ICLR
ICON PLC
$26.02BN/A0.00%N/AN/AN/AN/A
STRR
STAR EQUITY HOLDINGS INC
$13.95MN/A0.00%$0.5500N/AN/A0
FONR
FONAR CORP
$102.27MN/A0.00%N/AN/AN/AN/A
TMO
THERMO FISHER SCIENTIFIC INC
$227.24B0.24%9.20%$0.3900$1.443%0
IDXX
IDEXX LABORATORIES INC
$44.88BN/A0.00%N/AN/AN/AN/A
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
$11.42BN/A0.00%N/AN/AN/AN/A
ENZ
ENZO BIOCHEM INC
$55.84MN/A0.00%N/AN/AN/AN/A
DGX
QUEST DIAGNOSTICS INC
$16.03B2.00%38.20%$0.7500$2.8841%02024-07-082024-07-22
MEDP
MEDPACE HOLDINGS INC
$12.19BN/A0.00%N/AN/AN/AN/A
SHC
SOTERA HEALTH CO
$3.20BN/A0.00%N/AN/AN/AN/A
NEOG
NEOGEN CORP
$2.93BN/A0.00%N/AN/AN/AN/A
LAB
STANDARD BIOTOOLS INC
$956.40MN/A0.00%N/AN/AN/AN/A
A
AGILENT TECHNOLOGIES INC
$45.20B0.60%21.60%$0.2360$0.9210%1
QGEN
QIAGEN NV
$10.23B2.80%87.20%$1.2800$1.2853%0
DHR
DANAHER CORP
$196.87B0.40%17.60%$0.2700$1.056%22024-06-282024-07-26
FLGT
FULGENT GENETICS INC
$661.63MN/A0.00%N/AN/AN/AN/A
SERA
SERA PROGNOSTICS INC
$269.72MN/A0.00%N/AN/AN/AN/A
CSTL
CASTLE BIOSCIENCES INC
$669.20MN/A0.00%N/AN/AN/AN/A
EXAS
EXACT SCIENCES CORP
$9.30BN/A0.00%N/AN/AN/AN/A
NTRA
NATERA INC
$13.07BN/A0.00%N/AN/AN/AN/A
PRE
PRENETICS GLOBAL LTD
$70.84MN/A0.00%N/AN/AN/AN/A
RVTY
REVVITY INC
$13.60B0.25%23.00%$0.0700$0.283%02024-07-192024-08-09
CHEK
CHECK-CAP LTD
$12.78MN/A0.00%N/AN/AN/AN/A
OLK
OLINK HOLDING AB (PUBL)
$2.98BN/A0.00%N/AN/AN/AN/A
LH
LABCORP HOLDINGS INC
$17.75B1.03%56.50%$0.7200$2.1620%02024-05-282024-06-12
WAT
WATERS CORP
$21.11BN/A0.00%N/AN/AN/AN/A
PRPO
PRECIPIO INC
$9.24MN/A0.00%N/AN/AN/AN/A
DRIO
DARIOHEALTH CORP
$56.85MN/A0.00%N/AN/AN/AN/A
NEO
NEOGENOMICS INC
$1.89BN/A0.00%N/AN/AN/AN/A
TWST
TWIST BIOSCIENCE CORP
$2.74BN/A0.00%N/AN/AN/AN/A
IQV
IQVIA HOLDINGS INC
$42.12BN/A0.00%N/AN/AN/AN/A
MTD
METTLER TOLEDO INTERNATIONAL INC
$32.52BN/A0.00%N/AN/AN/AN/A
BNR
BURNING ROCK BIOTECH LTD
$85.03MN/A0.00%N/AN/AN/AN/A
ACRS
ACLARIS THERAPEUTICS INC
$84.81MN/A0.00%N/AN/AN/AN/A
RDNT
RADNET INC
$4.24BN/A0.00%N/AN/AN/AN/A
CDNA
CAREDX INC
$807.30MN/A0.00%N/AN/AN/AN/A
PSNL
PERSONALIS INC
$72.71MN/A0.00%N/AN/AN/AN/A
STIM
NEURONETICS INC
$78.29MN/A0.00%N/AN/AN/AN/A
ME
23ANDME HOLDING CO
$283.47MN/A0.00%N/AN/AN/AN/A
GH
GUARDANT HEALTH INC
$3.10BN/A0.00%N/AN/AN/AN/A
XWEL
XWELL INC
$7.28MN/A0.00%N/AN/AN/AN/A
OCX
ONCOCYTE CORP
$39.16MN/A0.00%N/AN/AN/AN/A
MYGN
MYRIAD GENETICS INC
$2.29BN/A0.00%N/AN/AN/AN/A
DMTK
DERMTECH INC
$17.45MN/A0.00%N/AN/AN/AN/A
XGN
EXAGEN INC
$32.66MN/A0.00%N/AN/AN/AN/A
PRPH
PROPHASE LABS INC
$95.97MN/A0.00%$0.3000N/AN/A0
AWH
ASPIRA WOMEN's HEALTH INC
$33.12MN/A0.00%N/AN/AN/AN/A
NDRA
ENDRA LIFE SCIENCES INC
$3.39MN/A0.00%N/AN/AN/AN/A
VNRX
VOLITIONRX LTD
$63.77MN/A0.00%N/AN/AN/AN/A
MDXH
MDXHEALTH SA
$7.86MN/A0.00%N/AN/AN/AN/A
GENE
GENETIC TECHNOLOGIES LTD
$526.30kN/A0.00%N/AN/AN/AN/A
NOTV
INOTIV INC
$50.12MN/A0.00%N/AN/AN/AN/A
BIAF
BIOAFFINITY TECHNOLOGIES INC
$26.35MN/A0.00%N/AN/AN/AN/A
MYNZ
MAINZ BIOMED NV
$14.39MN/A0.00%N/AN/AN/AN/A
ILMN
ILLUMINA INC
$17.69BN/A0.00%N/AN/AN/AN/A
OPK
OPKO HEALTH INC
$920.03MN/A0.00%N/AN/AN/AN/A
PMD
PSYCHEMEDICS CORP
$14.98M2.71%-9.10%$0.0700$0.0752%1
APDN
APPLIED DNA SCIENCES INC
$2.47MN/A0.00%N/AN/AN/AN/A
TRIB
TRINITY BIOTECH PLC
$12.11MN/A0.00%$1.1000N/AN/A0
BDSX
BIODESIX INC
$180.63MN/A0.00%N/AN/AN/AN/A
MMA
ALTA GLOBAL GROUP LTD
N/AN/A0.00%N/AN/AN/AN/A
ISPC
ISPECIMEN INC
$2.40MN/A0.00%N/AN/AN/AN/A
TTOO
T2 BIOSYSTEMS INC
$49.59MN/A0.00%N/AN/AN/AN/A
CNTG
CENTOGENE NV
$10.21MN/A0.00%N/AN/AN/AN/A
1

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in May 2024?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Icon (NASDAQ:ICLR)


Icon (NASDAQ:ICLR) is the top diagnostic & research stock with a Zen Score of 47, which is 21 points higher than the diagnostic & research industry average of 26. It passed 15 out of 33 due diligence checks and has strong fundamentals. Icon has seen its stock return 49.4% over the past year, overperforming other diagnostic & research stocks by 38 percentage points.

Icon has an average 1 year price target of $344.38, an upside of 9.42% from Icon's current stock price of $314.72.

Icon stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Icon, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Star Equity Holdings (NASDAQ:STRR)


Star Equity Holdings (NASDAQ:STRR) is the second best diagnostic & research stock with a Zen Score of 46, which is 20 points higher than the diagnostic & research industry average of 26. It passed 18 out of 38 due diligence checks and has strong fundamentals. Star Equity Holdings has seen its stock return 10% over the past year, underperforming other diagnostic & research stocks by -1 percentage points.

3. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the third best diagnostic & research stock with a Zen Score of 43, which is 17 points higher than the diagnostic & research industry average of 26. It passed 13 out of 33 due diligence checks and has strong fundamentals. Fonar has seen its stock lose -9.98% over the past year, underperforming other diagnostic & research stocks by -21 percentage points.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)


Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 2.8%, which is 2 percentage points higher than the diagnostic & research industry average of 1.25%.

Qiagen Nv's dividend payout ratio of 87.2% indicates that its dividend yield is sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)


Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 2%, which is 1 percentage points higher than the diagnostic & research industry average of 1.25%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 38.2% indicates that its dividend yield is sustainable for the long-term.

3. Labcorp Holdings (NYSE:LH)


Labcorp Holdings (NYSE:LH) has an annual dividend yield of 1.03%, which is the same as the diagnostic & research industry average of 1.25%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 56.5% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -0.44% in the last day, and up 1.56% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Star Equity Holdings (NASDAQ:STRR)


Star Equity Holdings (NASDAQ:STRR) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Star Equity Holdings has a valuation score of 71, which is 53 points higher than the diagnostic & research industry average of 18. It passed 5 out of 7 valuation due diligence checks.

Star Equity Holdings's stock has gained 10% in the past year. It has underperformed other stocks in the diagnostic & research industry by -1 percentage points.

2. Enzo Biochem (NYSE:ENZ)


Enzo Biochem (NYSE:ENZ) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Enzo Biochem has a valuation score of 71, which is 53 points higher than the diagnostic & research industry average of 18. It passed 5 out of 7 valuation due diligence checks.

Enzo Biochem's stock has dropped -52.81% in the past year. It has underperformed other stocks in the diagnostic & research industry by -64 percentage points.

3. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fonar has a valuation score of 71, which is 53 points higher than the diagnostic & research industry average of 18. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has dropped -9.98% in the past year. It has underperformed other stocks in the diagnostic & research industry by -21 percentage points.

Are diagnostic & research stocks a good buy now?

52.08% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 5.02% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 38.96x.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.